Bimonthly Survey

Please indicate if you have used resources and/or trainings from any of the following in the past 12 months.
Select all that apply
Are you familiar with the AETC Program HIV Care Tools App?
Graphic image

Join the Midwest AETC for a 2-part series on Long-Acting Injectable (LAI) medications for HIV PrEP. The first session involves an industry talk with two Medical Scientist Liaisons who will share the science and research behind their medications - Lenacapavir and Cabotegravir. This program offers a unique opportunity to engage directly with the industry experts involved in bringing these critical new prevention tools to the forefront of HIV care.

Objectives

  • Explain the mechanism of action for long-acting injectable medications for HIV PrEP
  • Understand the prescribing information for long-acting injectable medications for HIV PrEP
     
  • Summarize clinical trial data that lead to FDA approval of long-acting injectables for HIV PrEP

Speakers

Nicholas Olson, Pharm.D., BCACP, FPSW 
Senior Medical Scientist- HIV Medical Affairs 
Gilead Sciences, Inc.

Ryan Kates, Pharm.D., BCACP  
Medical Science Liaison-Midwest ViiV Healthcare

More events in this series